Pluri (PLUR) Net Income towards Common Stockholders (2010 - 2025)
Pluri (PLUR) posted quarterly Net Income towards Common Stockholders of $9.0 billion for Q4 2025, up 62.24% year-over-year from $5.5 billion in Q4 2024, and up 12.66% quarter-over-quarter from $8.0 billion in Q3 2025.
Pluri (PLUR) Net Income towards Common Stockholders (2010 - 2025) Analysis & Trends
Pluri (PLUR) has reported Net Income towards Common Stockholders for 16 consecutive years, with $9.0 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Income towards Common Stockholders rose 62.24% year-over-year to $9.0 billion; the TTM figure through Dec 2025 stood at $17.0 billion (up 54.49% YoY), while the FY2025 annual figure was $6.3 billion, up 20.95% from the prior year.
- Net Income towards Common Stockholders rose to $9.0 billion in Q4 2025 per PLUR's latest filing, from $8.0 billion in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $9.0 billion in Q4 2025 and bottomed at -$14.6 million in Q2 2021.
- Historically, Net Income towards Common Stockholders has averaged $1.4 billion across 5 years, with a median of -$6.1 million in 2024.
- On a YoY basis, Net Income towards Common Stockholders climbed as much as 113017.74% in 2024 and fell as far as 203.51% in 2024.
- Pluri's Net Income towards Common Stockholders stood at -$11.2 million in 2021, then grew by 24.17% to -$8.5 million in 2022, then soared by 157.94% to $4.9 million in 2023, then jumped by 113017.74% to $5.5 billion in 2024, then jumped by 62.24% to $9.0 billion in 2025.
- Business Quant data shows PLUR's Net Income towards Common Stockholders at $9.0 billion in Q4 2025, $8.0 billion in Q3 2025, and -$6.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Pluri | 16.21 Mn | 3.72 Mn | 86,000.00 | 9.00 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.00 Bn |
| Sep 30, 2025 | 7.99 Bn |
| Jun 30, 2025 | -6.85 Mn |
| Mar 31, 2025 | -5.61 Mn |
| Dec 31, 2024 | 5.55 Bn |
| Sep 30, 2024 | 5.45 Bn |
| Jun 30, 2024 | -6.25 Mn |
| Mar 31, 2024 | -5.92 Mn |
| Dec 31, 2023 | 4.91 Mn |
| Sep 30, 2023 | 4.96 Mn |
| Jun 30, 2023 | 6.04 Mn |
| Mar 31, 2023 | 7.76 Mn |
| Dec 31, 2022 | -8.47 Mn |
| Sep 30, 2022 | -6.46 Mn |
| Jun 30, 2022 | -9.17 Mn |
| Mar 31, 2022 | -10.14 Mn |
| Dec 31, 2021 | -11.17 Mn |
| Sep 30, 2021 | -11.66 Mn |
| Jun 30, 2021 | -14.65 Mn |
| Mar 31, 2021 | -14.44 Mn |